NanoViricides, Inc. Added to the Ludlow Biotech Index
BUSINESS WIRE
Posted: 2008-07-21 11:16:05
WEST HAVEN, Conn.--(BUSINESS WIRE)----NanoViricides, Inc. (OTC BB: NNVC.OB) a development stage company that is creating special purpose nanomaterials for the treatment of viral infections, today announced that the company has been added to the Ludlow Biotech Index.
Tom Bustamante, the Managing Partner of Ludlow BioVentures commented, "NanoViricides utilizes creative and unique nanomaterials for targeting and destroying viruses. The company's nanoviricides(TM) drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. NanoViricides, Inc. is thus creating treatments that need to be given only to patients that contract a viral disease, as opposed to vaccines, which must be given to substantially the entire population to prevent the occurrence of an epidemic. Nanoviricide drugs form a novel class of drugs, that is complementary to other existing viral therapies. This unique approach makes NNVC an interesting play in the field of viral therapy, and should provide for additional depth to our biotechnology stock index."
The Ludlow Biotech Index is a diverse basket of biotechnology stocks, that includes well established biotech stocks such as Amgen , Biogen -Idec, and Genzyme . This index provides institutional investors a means to track and trade a basket of small cap biotechnology stocks, with reduced risk through diversification. The Ludlow Biotech Index is owned and operated by Ludlow Capital Group, Inc.
For additional information on the Ludlow Biotech Index and its components visit ludlowcapital.com |
